Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Recruiting 3Not yet recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4

Conditions

Ovarian Neoplasms 3Fallopian Tube Neoplasms 2Ovarian Cancer Recurrent 1

Interventions

Paclitaxel 41Specimen Handling 36Carboplatin 34pembrolizumab 32Bevacizumab 32Magnetic Resonance Spectroscopy 29olaparib 19liposomal doxorubicin 16Cisplatin 16Biopsy 16Gemcitabine 15Taxes 12Nivolumab 12Immunoglobulin G 11Disulfides 11Cyclophosphamide 11Topotecan 10Doxorubicin 10fludarabine 9niraparib 7mirvetuximab soravtansine 7Fulvestrant 7trastuzumab deruxtecan 6palbociclib 6durvalumab 6Surveys and Questionnaires 6Megestrol Acetate 6lenvatinib 5dostarlimab 5Radiation 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
1-dodecylpyridoxal × Gynecologic × 30 days × Clear all
NCT07564141 2026-06-03

RAINFOLâ„¢-07

Genmab

Phase 3 Not yet recruiting
688 enrolled
Gynecologic

Ovarian Neoplasms

NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
460 enrolled
Gynecologic

Ovarian Cancer Recurrent

NCT06161025 2026-05-22

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Daiichi Sankyo

Phase 2/3 Recruiting
860 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06787612 2026-05-20

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Regeneron Pharmaceuticals

Phase 2 Recruiting
220 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡